PURPOSE: To determine the characteristics and outcome of patients with refractory gestational trophoblastic neoplasia (GTN) after primary chemotherapy (CTx). METHODS: The outcome of low- and high-risk patients with refractory GTN (n = 14, 37%) was compared to those with non-refractory GTN (n = 24, 63%). Methotrexate treatment was used for patients with low-risk disease and EMA/CO for patients with high-risk disease. RESULTS: Median follow-up time was 53 months (range 1-173 months). All non-refractory patients and 11 refractory patients (79%) survived (p = 0.015). Factors related to resistance to primary CTx was age (p = 0.012), duration between causal pregnancy and initial treatment (p = 0.003), surgery (p = 0.014), hCG level before CTx (p = 0.09) and half-life of hCG (p = 0.061). Six out of 10 low-risk refractory patients treated with EMA/CO regimen in the second-line setting had been followed by no evidence of disease. Nine of 38 (24%) patients underwent surgery (TAH ± BSO) for GTN. All of the patients treated with surgery were in the non-refractory group, but none of refractory patients underwent surgery (p = 0.014). CONCLUSIONS: Surgery and EMA/CO regimen are one of the main factors that play a role in the management of refractory low-risk GTN.
PURPOSE: To determine the characteristics and outcome of patients with refractory gestational trophoblastic neoplasia (GTN) after primary chemotherapy (CTx). METHODS: The outcome of low- and high-risk patients with refractory GTN (n = 14, 37%) was compared to those with non-refractory GTN (n = 24, 63%). Methotrexate treatment was used for patients with low-risk disease and EMA/CO for patients with high-risk disease. RESULTS: Median follow-up time was 53 months (range 1-173 months). All non-refractory patients and 11 refractory patients (79%) survived (p = 0.015). Factors related to resistance to primary CTx was age (p = 0.012), duration between causal pregnancy and initial treatment (p = 0.003), surgery (p = 0.014), hCG level before CTx (p = 0.09) and half-life of hCG (p = 0.061). Six out of 10 low-risk refractory patients treated with EMA/CO regimen in the second-line setting had been followed by no evidence of disease. Nine of 38 (24%) patients underwent surgery (TAH ± BSO) for GTN. All of the patients treated with surgery were in the non-refractory group, but none of refractory patients underwent surgery (p = 0.014). CONCLUSIONS: Surgery and EMA/CO regimen are one of the main factors that play a role in the management of refractory low-risk GTN.
Authors: I A McNeish; S Strickland; L Holden; G J S Rustin; M Foskett; M J Seckl; E S Newlands Journal: J Clin Oncol Date: 2002-04-01 Impact factor: 44.544
Authors: Whitfield B Growdon; Adam J Wolfberg; Donald P Goldstein; Colleen M Feltmate; Manuel E Chinchilla; Ellice S Lieberman; Ross S Berkowitz Journal: J Reprod Med Date: 2010 Jul-Aug Impact factor: 0.142
Authors: Peter Schmid; Yutaka Nagai; Roshan Agarwal; Barry Hancock; Philip M Savage; Neil J Sebire; Iain Lindsay; Michael Wells; Rosemary A Fisher; Delia Short; Edward S Newlands; Manfred B Wischnewsky; Michael J Seckl Journal: Lancet Date: 2009-06-22 Impact factor: 79.321